Announcement • Jun 09
Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 30, 2026 Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 30, 2026, at 10:30 China Standard Time. Location: 30/f, harbour side hq, 8 lam chak street, kowloon bay, Hong Kong New Risk • Jun 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$23m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (HK$229.2m market cap, or US$29.3m). New Risk • Mar 28
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$107m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (HK$305.6m market cap, or US$39.0m). Announcement • Mar 16
Zhong Ji Longevity Science Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 Zhong Ji Longevity Science Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026 Announcement • Aug 18
Zhong Ji Longevity Science Group Limited to Report First Half, 2025 Results on Aug 28, 2025 Zhong Ji Longevity Science Group Limited announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Aug 05
Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a non-legally binding memorandum of understanding to acquire Asian Integrated Cell Laboratory Limited from China International Osteoarticular Medical Group Limited. Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a non-legally binding memorandum of understanding to acquire Asian Integrated Cell Laboratory Limited from China International Osteoarticular Medical Group Limited on August 4, 2025. New Risk • Jun 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (HK$308.8m market cap, or US$39.3m). Announcement • Jun 26
Zhong Ji Longevity Science Group Limited has completed a Follow-on Equity Offering in the amount of HKD 30.642415 million. Zhong Ji Longevity Science Group Limited has completed a Follow-on Equity Offering in the amount of HKD 30.642415 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 90,124,751
Price\Range: HKD 0.34
Transaction Features: Subsequent Direct Listing Announcement • Jun 18
Zhong Ji Longevity Science Group Limited has filed a Follow-on Equity Offering in the amount of HKD 30.642415 million. Zhong Ji Longevity Science Group Limited has filed a Follow-on Equity Offering in the amount of HKD 30.642415 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 90,124,751
Price\Range: HKD 0.34
Transaction Features: Subsequent Direct Listing Announcement • Jun 17
Zhong Ji Longevity Science Group Limited has filed a Follow-on Equity Offering in the amount of HKD 30.642416 million. Zhong Ji Longevity Science Group Limited has filed a Follow-on Equity Offering in the amount of HKD 30.642416 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 92,855,806
Price\Range: HKD 0.33
Transaction Features: Subsequent Direct Listing Announcement • Apr 28
Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 27, 2025 Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 27, 2025, at 10:30 China Standard Time. Location: 30/f, harbour side hq, 8 lam chak street, kowloon bay, Hong Kong Announcement • Mar 18
Zhong Ji Longevity Science Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 Zhong Ji Longevity Science Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Jan 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (HK$99.5m market cap, or US$12.8m). Announcement • Aug 16
Zhong Ji Longevity Science Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Zhong Ji Longevity Science Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jul 10
Zhong Ji Longevity Science Group Limited Announces Board and Committee Changes The Board of Zhong Ji Longevity Science Group Limited announced that with effect from 10 July 2024: Mr. HUANG Jiang have been appointed as independent non-executive Director. Mr. WANG Ning has resigned as an independent non-executive Director due to the pursuit of personal and other business commitments. Mr. WANG Ning ceased to act as the chairman of the remuneration committee and a member of each of the nomination committee, the audit committee, the risk management committee and the share award committee of the Board; Mr. HUANG Jiang has been appointed as the chairman of the remuneration committee and a member of each of the nomination committee, the audit committee, the risk management committee and the share award committee of the Board. Mr. Huang, aged 42, holds an Executive Master of Business Administration from the United Business Institutes and an Executive Master of Business Administration from Jinan University. Mr. Huang was the first-generation golf commentator in China. He has experience in multimedia operations such as founding Golf Trip Magazine and initiated well-known golf events such as the Asian Star Golf Charity Tournament, the Hanlin Cup National College Golf Classic, the Star Enterprise Charity League, and the Chaoshan open tournament. He has served as the executive director of the China Health Industry Alliance. Mr. Huang is familiar with a variety of investment scopes including includes finance, culture and sports, movies, real estate properties, upstream and downstream industrial parks. He has rich experience and capabilities in commercial investment operations and enterprise management. New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (HK$202.2m market cap, or US$25.9m). New Risk • May 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (HK$109.3m market cap, or US$14.0m). Announcement • Mar 15
Zhong Ji Longevity Science Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Zhong Ji Longevity Science Group Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 New Risk • Oct 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$77.9m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (HK$77.9m market cap, or US$9.95m). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Announcement • Aug 16
Zhong Ji Longevity Science Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Zhong Ji Longevity Science Group Limited announced that they will report first half, 2023 results on Aug 23, 2023 Announcement • May 30
Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 29, 2023 Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jun 29, 2023, at 10:30 China Standard Time. Location: 30/F., Harbour Side HQ 8 Lam Chak Street Kowloon Bay Hong Kong Agenda: To receive and consider the audited consolidated financial statements and the reports of the directors of the Company and the auditors of the Company for the year ended 31 December 2022; to re-elect Mr. Yan Yifan as an executive director of the Company; to re-elect Ms. Cao Xie Qiong as an executive director of the Company; to re-elect Mr. Lyn Changsheng as a non-executive director of the Company; to re-elect Mr. Lee See Barry as an independent non-executive director of the Company; to authorise the board of Directors to fix the remuneration of the Directors for the upcoming year; to re-appoint Elite Partners CPA Limited as auditor of the Company and to authorise the Board to fix its remuneration; and to consider other matters. Announcement • May 04
Zhong Ji Longevity Science Group Limited has completed a Follow-on Equity Offering in the amount of HKD 14.5677 million. Zhong Ji Longevity Science Group Limited has completed a Follow-on Equity Offering in the amount of HKD 14.5677 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 297,300,000
Price\Range: HKD 0.049
Discount Per Security: HKD 0.002
Transaction Features: Subsequent Direct Listing Board Change • Apr 19
Less than half of directors are independent There are 10 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Executive Chairman of the Board Li Yan is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Ning Wang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Feb 08
Insider recently bought HK$12m worth of stock On the 31st of January, Pap Butani bought around 240m shares on-market at roughly HK$0.05 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold HK$15m more in shares than they bought in the last 12 months. Board Change • Nov 16
Less than half of directors are independent There are 10 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Executive Chairman of the Board Li Yan is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Ning Wang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Aug 17
Zhong Ji Longevity Science Group Limited to Report First Half, 2022 Results on Aug 29, 2022 Zhong Ji Longevity Science Group Limited announced that they will report first half, 2022 results on Aug 29, 2022 Announcement • Aug 04
Zhong Ji Longevity Science Group Limited Announces Board Changes Zhong Ji Longevity Science Group Limited announced that Ms. Choi Ngai Wah has resigned as a non-executive Director due to the pursuit of personal and other business commitments with effect from 3 August 2022. Announcement • Aug 02
Zhong Ji Longevity Science Group Limited Announces Appointment of Mr. Lyu Changsheng as Non-Executive Director The board of directors of Zhong Ji Longevity Science Group Limited announced that Mr. Lyu Changsheng has been appointed as a non-executive Director with effect from 1 August 2022. Mr. Lyu, aged 62, has extensive leadership experience in investment consulting. Over the past 20 years, he has proven to possess progressive and comprehensive corporate development knowledge. Mr. Lyu is familiar with a variety of management functions of an organization including initiating, developing and implementing procedures to improve business performance. He has experience in the past serve in various listing entity as chairman of the board or as executive director, no limited to but includes DeTai New Energy Group Limited. Mr. Lyu has entered into an appointment letter with the Company with an initial term of two years. Recent Insider Transactions • Jun 29
Executive Chairman of the Board recently sold HK$15m worth of stock On the 23rd of June, Li Yan sold around 303m shares on-market at roughly HK$0.051 per share. This was the largest sale by an insider in the last 3 months. Li has been a seller over the last 12 months, reducing personal holdings by HK$18m. Announcement • Jun 01
Zhong Ji Longevity Science Group Limited Announces Change of Company Secretary and Authorized Representatives Zhong Ji Longevity Science Group Limited announces that Mr. Liu Wai Kin (``Mr. Liu'') has tendered his resignation as the company secretary of the Company (the ``Company Secretary''), an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ``Stock Exchange'') and an authorised representative of the Company for accepting service of process or notice in Hong Kong under the Companies Ordinance, with effect from 31 May 2022. Mr. Liu has confirmed to the Board that there is no disagreement with the Board and no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company. The Board also announced that Mr. Wan San Fai, Vincent (``Mr. Wan'') has been appointed as the Company Secretary and Authorised Representatives with effect from 31May 2022. Mr. Wan, aged 48, holds a Bachelor of Arts degree in Accountancy from the Hong Kong Polytechnic University. He is a member of The Hong Kong Institute of Certified Public Accountants. He has been the chief financial officer and company secretary of Pan Asia Environmental Protection Group Limited (Stock code: 00556.HK) since 2007. Mr. Wan has more than 20 years' experience in auditing, accounting and financial management. The Board would like to express its appreciation to Mr. Liu for his contribution to the Company during his tenure of office and welcome Mr. Wan for his new appointment. Announcement • May 28
Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jul 29, 2022 Zhong Ji Longevity Science Group Limited, Annual General Meeting, Jul 29, 2022. Board Change • Apr 27
Less than half of directors are independent There are 10 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Executive Chairman of the Board Li Yan is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Ning Wang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Apr 20
Zhong Ji Longevity Science Group Limited to Report Fiscal Year 2021 Results on Apr 29, 2022 Zhong Ji Longevity Science Group Limited announced that they will report fiscal year 2021 results on Apr 29, 2022 Announcement • Apr 14
Zhong Ji Longevity Science Group Limited Announces Board Changes Zhong Ji Longevity Science Group Limited's Board announced that with effect from 11 April 2022: Mr. Tam Ho Leung has resigned as an independent non-executive director of the Company due to personal and other business affairs. Mr. Tam Ho Leung Simon ceased to be the chairman of the audit committee and a member of each of the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board; and Mr. Lee See Barry has been appointed as the chairman of the audit committee of the Board. Announcement • Apr 03
Zhong Ji Longevity Science Group Limited Announces Earnings Guidance for the Year Ended December 31, 2021 Zhong Ji Longevity Science Group Limited announced earnings guidance for the year ended December 31, 2021. For the year, the company expected to record a marked turnaround to net profit after tax of not less than HKD 18 million for the Year, as compared with a net loss after tax of the Group of approximately 10.7 million recorded by the Group for the year ended 31 December 2020. The expected net profit for the Year is mainly attributable to the following: (i) the substantial decrease in impairment of financial assets due to the decrease in impairment loss recognized in respect of loan for the Year; and (ii) the growth of the longevity science business of the Group which commenced to generate income during the Year. Announcement • Apr 01
Zhong Ji Longevity Science Group Limited Announces Management Appointments The board of directors of Zhong Ji Longevity Science Group Limited announced that Lee See Barry has been appointed as an independent non-executive Director and a member of each of the Audit Committee, Remuneration Committee, Nomination Committee and Share Award Committee of the Board with effect from March 31, 2022. Lee has over 30 years of experience in audit, accounting and financial management. He has served as a senior partner of Sysble Consultants since 2005, during which, it serves as the financial controller of its major customers, China CBM Group and Oriental Speech Therapy. In order to improve the risk management of the Company, the Board has established the Risk Management Committee in accordance with the Bye-laws of the Company with effect from March 31, 2022. The members of the Risk Management Committee are Tam Ho Leung Simon, Wang Weixia, Chai Nan and Lee See Barry has been appointed as the chairman of the Risk Management Committee. Announcement • Mar 23
Zhong Ji Longevity Science Group Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Zhong Ji Longevity Science Group Limited announced that they will report fiscal year 2021 results on Mar 31, 2022 Announcement • Mar 01
Zhong Ji Longevity Science Group Limited Announces Executive Changes The board of directors of Zhong Ji Longevity Science Group Limited announced that Chen Ning has been appointed as the chairman of the China Region and Chief Investment Officer to take on full responsibility for the Group's money lending and financial business, with effect from February 28, 2022. Chen is currently an independent director of Hainan Life Insurance Company Limited and Chao Shang Dong Meng Investment Fund Management Company Limited. The board also announced that Wang Hongxin has resigned as Chief Investment Officer and chairman of the China Region due to personal and other business commitments. Announcement • Feb 22
Zhong Ji Longevity Science Group Limited (SEHK:767) entered into an agreement to acquire Fame Star Properties Limited from Yau King Kwok Andrew for HKD 12.6 million. Zhong Ji Longevity Science Group Limited (SEHK:767) entered into an agreement to acquire Fame Star Properties Limited from Yau King Kwok Andrew for HKD 12.6 million on February 18, 2022. The consideration includes HKD 7.35 million for share acquisition and HKD 5.25 million for the vendor loan acquisition. The consideration will be financed from internal sources of Zhong Ji Longevity Science Group. For the period ended March 31, 2021, Fame Star reported revenue of approximately HKD 4.7 million and net income of approximately HKD 1.9 million. Fame Stare had a total common equity of HKD 3.8 million as reported on January 31, 2021. The acquisition is subject to consummation of due diligence by Zhong Ji Longevity Science Group. Completion shall take place on the third business day after the fulfillment or waiver of the conditions precedent in the acquisition agreement. Announcement • Jan 22
Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a memorandum of understanding to acquire Hong Kong Credit Finance Limited. Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a memorandum of understanding to acquire Hong Kong Credit Finance Limited on January 20, 2022. Recent Insider Transactions • Nov 03
Insider recently sold HK$246m worth of stock On the 29th of October, Rutong Jia sold around 492m shares on-market at roughly HK$0.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of HK$328m more than they bought in the last 12 months. Executive Departure • Sep 14
Chief Financial Officer Youhua Chen has left the company During their tenure, earnings grew by 1,694% annually compared to the industry average of 8.4%. On the 10th of September, Youhua Chen left the company after less than a year in the role. We don't have any record of a personal shareholding under Youhua's name. A total of 9 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Recent Insider Transactions • Aug 27
Insider recently sold HK$4.7m worth of stock On the 24th of August, Rutong Jia sold around 9m shares on-market at roughly HK$0.54 per share. In the last 3 months, they made an even bigger sale worth HK$20m. Insiders have been net sellers, collectively disposing of HK$82m more than they bought in the last 12 months. Announcement • Aug 19
Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a memorandum of understanding to acquire an unknown majority stake in Zhejiang Aiminde Biological Technology Co., Ltd. Zhong Ji Longevity Science Group Limited (SEHK:767) entered into a memorandum of understanding to acquire an unknown majority stake in Zhejiang Aiminde Biological Technology Co., Ltd. on August 18, 2021. The transaction was for 51% stake or more. For the year ending December 31, 2020, Zhejiang Aiminde Biological Technology Co., Ltd. reported sales revenue of CNY 650 million. Recent Insider Transactions • Jun 26
Insider recently sold HK$10.0m worth of stock On the 23rd of June, Rutong Jia sold around 19m shares on-market at roughly HK$0.54 per share. In the last 3 months, they made an even bigger sale worth HK$20m. Insiders have been net sellers, collectively disposing of HK$57m more than they bought in the last 12 months. Recent Insider Transactions • Jun 24
Insider recently sold HK$20m worth of stock On the 15th of June, Rutong Jia sold around 36m shares on-market at roughly HK$0.56 per share. In the last 3 months, they made an even bigger sale worth HK$20m. Insiders have been net sellers, collectively disposing of HK$47m more than they bought in the last 12 months. Recent Insider Transactions • Jun 12
Insider recently sold HK$20m worth of stock On the 10th of June, Rutong Jia sold around 36m shares on-market at roughly HK$0.56 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of HK$27m more than they bought in the last 12 months. Executive Departure • May 28
Executive Director has left the company On the 21st of May, Siu Keung Yeung's tenure as Executive Director ended after 1.4 years in the role. We don't have any record of a personal shareholding under Siu Keung's name. A total of 9 executives have left over the last 12 months. Recent Insider Transactions • May 27
Insider recently sold HK$7.1m worth of stock On the 25th of May, Rutong Jia sold around 10m shares on-market at roughly HK$0.71 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Announcement • May 12
Zhong Ji Longevity Science Group Limited announced that it expects to receive HKD 212.55 million in funding Zhong Ji Longevity Science Group Limited (SEHK:767) announced a best effort basis private placement of 250,000,000 Placing Shares at a price of HKD 0.65 per share for gross proceeds of HKD 162,500,000? and 77,000,000 Subscription Shares at a price of HKD 0.65 per share for the gross proceeds of HKD 50,050,000; for the aggregate gross proceeds of HKD 212,550,000 on May 10, 2021. The transaction will include participation from Yan Li, the chairman of the Board and an executive Director for 77,000,000 Subscription Shares. The securities issued in the transaction are subject to one year hold period. The transaction is subject to approval from shareholders of the company at SGM. Executive Departure • May 07
Independent Non-Executive Director has left the company On the 1st of May, Man Wai Ho's tenure as Independent Non-Executive Director ended after less than a year in the role. We don't have any record of a personal shareholding under Man Wai's name. A total of 8 executives have left over the last 12 months. Executive Departure • May 07
Non-Executive Director has left the company On the 1st of May, Yang Yu's tenure as Non-Executive Director ended after 3.6 years in the role. We don't have any record of a personal shareholding under Yang's name. A total of 8 executives have left over the last 12 months. Executive Departure • May 07
Independent Non-Executive Director has left the company On the 1st of May, Ping Leung Mak's tenure as Independent Non-Executive Director ended after less than a year in the role. We don't have any record of a personal shareholding under Ping Leung's name. A total of 8 executives have left over the last 12 months. Announcement • Mar 28
Zhong Ji Longevity Science Group Limited Provides Earnings Guidance for the Year Ended December 31, 2021 Zhong Ji Longevity Science Group Limited provided earnings guidance for the year ended December 31, 2021. For the year, the company expected the loss attributable to the owners of the company to decrease by not less than 80% as compared to the corresponding period in 2019. Announcement • Mar 19
Asia Pacific Silk Road Investment Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Asia Pacific Silk Road Investment Company Limited announced that they will report fiscal year 2020 results on Mar 30, 2021 Executive Departure • Mar 18
Independent Non-Executive Director has left the company On the 16th of March, Wai Dune Chan's tenure as Independent Non-Executive Director ended after less than a year in the role. We don't have any record of a personal shareholding under Wai Dune's name. A total of 4 executives have left over the last 12 months. Announcement • Mar 17
Asia Pacific Silk Road Investment Company Limited Announces Management Changes The board of directors of Asia Pacific Silk Road Investment Company Limited together with its subsidiaries, the announced that with effect from 16 March 2021, Ms. HO Man Wai and Ms. WANG Weixia have been appointed as independent non-executive Directors. Ms. Ho currently a senior manager of Nortex (HK) CPA Limited, and was previously the financial controller of a listed company in Hong Kong. Ms. Ho has entered into an appointment letter with the Company with an initial term of two years. Ms. Ho is subject to retirement by rotation and re-election (if applicable) at the annual general meeting at least once every three years. Ms. Wang is a partner of Guangdong Zhuojian Law Firm since 2013. She is an independent director of Guizhou Dongfeng Antimony Industry Co. Ltd. The Board announced that Mr. CHAN Wai Dune has resigned as an independent non-executive Director due to the pursuit of personal and other business commitments, with effect from 16 March 2021. Is New 90 Day High Low • Jan 25
New 90-day high: HK$0.92 The company is up 441% from its price of HK$0.17 on 27 October 2020. The Hong Kong market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 8.0% over the same period. Announcement • Jan 09
Asia Pacific Silk Road Investment Company Limited Appoints Chen Youhua as Chief Financial Officer The board of Asia Pacific Silk Road Investment Company Limited announced that Mr. Chen Youhua (Mr. Chen) has been appointed as the Chief Financial Officer with effect from 6 January 2021. Mr. Chen Youhua had been an executive director of Silk Road Energy Services Group Limited (Stock code: 8250), a company which shares are listed on the GEM Board of The Stock Exchange of Hong Kong Limited (the ``Stock Exchange''), during the period from 26 November 2012 to 31 December 2020. Mr. Chen had also appointed to act as chief executive officer of Silk Road Energy Services Group Limited, during the period from 13 June 2016 to 31 December 2020. Is New 90 Day High Low • Jan 06
New 90-day high: HK$0.47 The company is up 348% from its price of HK$0.11 on 08 October 2020. The Hong Kong market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 13% over the same period. Announcement • Jan 01
Asia Pacific Silk Road Investment Company Limited Announces Board Changes Asia Pacific Silk Road Investment Company Limited announced that with effect from 31 December 2020: (i) Ms. CHOI Ngai Wah has been appointed as a non-executive Director; (ii) Mr. CHAN Wai Dune and Mr. MAK Ping Leung have been appointed as independent non-executive Directors; and (iii) Mr. WONG Man Hong and Mr. ZHENG Zhen have resigned as independent non-executive Directors due to the pursuit of their personal and other business commitments. Changes in members of board committees. The Board also announces that with effect from 31 December 2020: (i) Mr. WONG Man Hong ceased to act as the chairman of each of the audit committee, the remuneration committee and the nomination committee of the Board; (ii) Mr. ZHENG Zhen ceased to act as a member of each of the audit committee, the remuneration committee and the nomination committee of the Board; (iii) Mr. CHAN Wai Dune has been appointed as the chairman of each of the audit committee and the remuneration committee and a member of the nomination committee of the Board;
(iv) Mr. YAN Li, the chairman of the Board, has been appointed as the chairman of the nomination committee of the Board; and (v) Mr. MAK Ping Leung has been appointed as a member of each of the audit committee, the remuneration committee and the nomination committee of the Board. Ms. Choi, aged 63, is currently the director of Intretech (HK) Co., Limited. Mr. Chan, aged 68, is currently the chairman and chief executive officer of Crowe (HK) CPA Limited. Announcement • Dec 18
Asia Pacific Silk Road Investment Company Limited Announces Executive Changes Asia Pacific Silk Road Investment Company Limited announced that with effect from 16 December 2020, Mr. YAN Li has been appointed as the Chairman of the Board; and Ms. CAO XIE Qiong has been appointed as an Executive Director. and also appointed Randy Wayne SCHEKMAN has been appointed as the Honorary Chairman and Chief Scientist of the Company with effect from December 16, 2020. Announcement • Nov 20
Asia Pacific Silk Road Investment Company Limited enters into the Distribution Agreement Asia Pacific Silk Road Investment Company Limited entered into the Distribution Agreement with HK Zhong Ji 1, pursuant to which HK Zhong Ji 1 has agreed to grant to the Distributor the non-exclusive right to distribute and sell the Health Products and the right to use the Trademarks. Announcement • Nov 14
Asia Pacific Silk Road Investment Company Limited Appoints Yan Li as Executive Director The board of directors of Asia Pacific Silk Road Investment Company Limited announced that Mr. Yan Li has been appointed as an executive Director of the company with effect from 13 November 2020. Mr. Yan is currently a director and the chief executive officer of HK Zhong Ji 1. Is New 90 Day High Low • Nov 06
New 90-day high: HK$0.21 The company is up 247% from its price of HK$0.06 on 07 August 2020. The Hong Kong market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 9.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day high: HK$0.20 The company is up 177% from its price of HK$0.073 on 31 July 2020. The Hong Kong market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is up 5.0% over the same period. Announcement • Aug 20
Asia Pacific Silk Road Investment Company Limited to Report First Half, 2020 Results on Aug 28, 2020 Asia Pacific Silk Road Investment Company Limited announced that they will report first half, 2020 results on Aug 28, 2020 
